Methotrexate

Generic Name: Methotrexate

Brand Names: Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₂N_₈O_₅

CAS Number: 59-05-2

Unique Ingredient Identifier: YL5FZ2Y5U1

Background: Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...

Indication: Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis

Associated Therapies: Medically induced abortion

Clinical Trials

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting

Conditions: Philadelphia-Positive ALL
Lymphoblastic Leukemia
Adult ALL

Interventions: Drug: Vincristine
Drug: Dexamethasone
Drug: Imatinib
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Ponatinib
Procedure: allogeneic stem cell transplantation
Procedure: Total body irradiation
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-12-19

Last Posted Date: 2023-12-19

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 150

Registration Number: NCT06175702

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Procedure: Biospecimen Collection
Procedure: Chest Computed Tomography
Procedure: Echocardiography
Procedure: Hematopoietic Cell Transplantation
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Drug: Ruxolitinib Phosphate
Drug: Tacrolimus

First Posted Date: 2023-11-13

Last Posted Date: 2024-10-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 40

Registration Number: NCT06128070

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

First Posted Date: 2023-11-09

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 680

Registration Number: NCT06124157

Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata

Not Applicable

Not yet recruiting

Conditions: Alopecia Areata

Interventions: Drug: Methotrexate
Drug: Triamcinolone Acetonide

First Posted Date: 2023-10-18

Last Posted Date: 2023-11-13

Lead Sponsor: Al-Azhar University

Target Recruit Count: 34

Registration Number: NCT06088147

Locations: 🇪🇬
Al-Azhar University, Assiut, Egypt

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Capecitabine

First Posted Date: 2023-10-17

Last Posted Date: 2024-01-12

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 25

Registration Number: NCT06085742

Locations: 🇺🇸
University of Illinois, Chicago, Illinois, United States

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Phase 4

Not yet recruiting

Conditions: Hypophosphatasia

Interventions: Drug: methotrexate
Drug: rituximab
Drug: bortezomib
Drug: IVIg
Drug: Folic Acid

First Posted Date: 2023-08-29

Last Posted Date: 2024-11-06

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 8

Registration Number: NCT06015750

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Phase 2

Recruiting

Conditions: Non-hodgkin Lymphoma

Interventions: Drug: Methotrexate
Drug: Rituximab (where available)
Drug: Ibrutinib

First Posted Date: 2023-08-21

Last Posted Date: 2024-11-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 30

Registration Number: NCT05998642

Locations: 🇨🇦
The Research Institute of the McGill University, Montreal, Quebec, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

and more 2 locations